Interestingly our findings predict that the R174Q and R177Q mutations may facilitate the AML-associated drug Enasidenib interaction with RUNX1 (pocket1), and could provide additional deleterious effect on its DNA binding (Song et al., 1999). Here, RUNX1 is linked to acute myeloid leukemia.